| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mirijam Fric, Gerd Lau. [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Psychiatrische Praxis. vol 30. issue Suppl 2. 2019-11-20. PMID:13130349. |
[prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine] elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine d2 receptor antagonism. |
2019-11-20 |
2023-08-12 |
Not clear |
| Charanraj Goud Alladi, Ravi Philip RajKumar, Surendiran Adithan, Cynthia Marie-Claire, Frank Bellivier, Deepak Gopal Shewad. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. Fundamental & clinical pharmacology. vol 33. issue 3. 2019-09-16. PMID:30332506. |
dopamine (drd2) and serotonin (htr2a, 2c) receptor gene polymorphisms do not influence early response to risperidone in south indian patients with schizophrenia. |
2019-09-16 |
2023-08-13 |
Not clear |
| Mariusz Papp, Piotr Gruca, Magdalena Lason-Tyburkiewicz, Ewa Litwa, Monika Niemczyk, Katarzyna Tota-Glowczyk, Agata Faron-Gorecka, Maciej Kusmider, Joanna Solich, Marta Szlachta, Paul Willne. Effects on brain-derived neurotrophic factor signalling of chronic mild stress, chronic risperidone and acute intracranial dopamine receptor challenges. Behavioural pharmacology. vol 29. issue 6. 2019-08-01. PMID:29537988. |
we have previously reported the effects of intracranial injections of dopamine d1, d2 and d3 ligands in animals subjected to the novel object recognition (nor) test following exposure to chronic mild stress (cms) and chronic treatment with risperidone (rsp). |
2019-08-01 |
2023-08-13 |
Not clear |
| F Tollens, N Gass, R Becker, A J Schwarz, C Risterucci, B Künnecke, P Lebhardt, J Reinwald, M Sack, W Weber-Fahr, A Meyer-Lindenberg, A Sartoriu. The affinity of antipsychotic drugs to dopamine and serotonin 5-HT European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 9. 2019-05-03. PMID:30006253. |
therefore, we examined the relationship between the affinities of three second-generation antipsychotics (amisulpride, risperidone and olanzapine) to dopamine and serotonin receptors and fc patterns related to the prefrontal cortex (pfc) and striatum in sprague-dawley rats. |
2019-05-03 |
2023-08-13 |
rat |
| Han Qing Li, Jia Yin Xu, Yuan Yuan Gao, Liang Ji. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes. Pharmacological research. vol 137. 2019-04-22. PMID:30281999. |
risperidone, one of the second-generation antipsychotics, can efficiently target dopamine d |
2019-04-22 |
2023-08-13 |
Not clear |
| Lingyue Ma, Xiaodan Zhang, Qian Xiang, Shuang Zhou, Nan Zhao, Qiufen Xie, Xia Zhao, Ying Zhou, Yimin Cu. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis. Basic & clinical pharmacology & toxicology. vol 124. issue 1. 2019-04-16. PMID:30103286. |
this study aimed to evaluate the relationship between genes of the dopamine receptors (d1, d2, and d3) and the effect of risperidone treatment. |
2019-04-16 |
2023-08-13 |
Not clear |
| Li Jing, Ben Liu, Min Zhang, Jian-Hui Lian. Involvement of dopamine D2 receptor in a single methamphetamine-induced behavioral sensitization in C57BL/6J mice. Neuroscience letters. vol 681. 2019-03-11. PMID:29501686. |
in the present study, we examined whether typical antipsychotic haloperidol and atypical antipsychotic risperidone, both targeting dopamine d2 receptor, could prevent the methamphetamine sensitization when they were given at the different phase of behavioral sensitization. |
2019-03-11 |
2023-08-13 |
mouse |
| Vincenzo G Fiore, Tobias Nolte, Francesco Rigoli, Peter Smittenaar, Xiaosi Gu, Raymond J Dola. Value encoding in the globus pallidus: fMRI reveals an interaction effect between reward and dopamine drive. NeuroImage. vol 173. 2019-01-28. PMID:29481966. |
to test this prediction, we used an fmri paradigm involving a within-subject placebo-controlled design, using the dopamine antagonist risperidone, wherein healthy volunteers performed a motor selection and maintenance task under low and high reward conditions. |
2019-01-28 |
2023-08-13 |
human |
| Vincenzo G Fiore, Tobias Nolte, Francesco Rigoli, Peter Smittenaar, Xiaosi Gu, Raymond J Dola. Value encoding in the globus pallidus: fMRI reveals an interaction effect between reward and dopamine drive. NeuroImage. vol 173. 2019-01-28. PMID:29481966. |
roi-based fmri analysis revealed an interaction between reward and dopamine drive manipulations, with increased bold activity in gpe in a high compared to low reward condition, and under risperidone compared to placebo. |
2019-01-28 |
2023-08-13 |
human |
| Katarzyna Kamińska, Anna Górska, Karolina Noworyta-Sokołowska, Adam Wojtas, Zofia Rogóż, Krystyna Gołembiowsk. The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex. Pharmacological reports : PR. vol 70. issue 5. 2018-11-16. PMID:30144663. |
the effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex. |
2018-11-16 |
2023-08-13 |
rat |
| Sheng Wang, Tao Che, Anat Levit, Brian K Shoichet, Daniel Wacker, Bryan L Rot. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature. vol 555. issue 7695. 2018-08-10. PMID:29466326. |
the drd2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at drd2. |
2018-08-10 |
2023-08-13 |
Not clear |
| Gurjit Kaur, Deepti Gupta, Bir Singh Chavan, Vikas Sinhmar, Rajendra Prasad, Adarsh Tripathi, P D Garg, Rajiv Gupta, Hitesh Khurana, Shiv Gautam, Mushtaq Ahmed Margoob, Jitender Anej. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. Asian journal of psychiatry. vol 29. 2018-06-22. PMID:28692863. |
so, we attempted to evaluate the association between dopamine d2 (drd2) receptor, serotonergic (5ht2a) receptor and cyp2d6 gene polymorphisms and response to treatment with risperidone in persons with schizophrenia from north india. |
2018-06-22 |
2023-08-13 |
Not clear |
| Katherine J Motyl, Megan Beauchemin, Deborah Barlow, Phuong T Le, Kenichi Nagano, Annika Treyball, Anisha Contractor, Roland Baron, Clifford J Rosen, Karen L Houseknech. A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice. Bone. vol 103. 2018-05-14. PMID:28689816. |
a novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice. |
2018-05-14 |
2023-08-13 |
mouse |
| Wei-Wei Sun, Lin-Yu Li, Xu-Feng Huang, Yan-Chuan Shi, He-Qin Yang, Zhi-Yuan Song, Shu Li. The central mechanism of risperidone-induced hyperprolactinemia. Progress in neuro-psychopharmacology & biological psychiatry. vol 76. 2018-04-02. PMID:28336493. |
furthermore, risperidone induced a decreased dopamine synthesis in the pvn and thus reduced the dopamine-induced inhibition of prolactin release, ultimately lead to hyperprolactinemia. |
2018-04-02 |
2023-08-13 |
mouse |
| Shinji Shimizu, Sandra M den Hoedt, Victor Mangas-Sanjuan, Sinziana Cristea, Jana K Geuer, Dirk-Jan van den Berg, Robin Hartman, Francisco Bellanti, Elizabeth C M de Lang. Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat. Drug metabolism and disposition: the biological fate of chemicals. vol 45. issue 2. 2018-02-14. PMID:27836941. |
to understand the drivers in the biological system response to dopamine d2 receptor antagonists, a mechanistic semiphysiologically based (pb) pharmacokinetic-pharmacodymanic (pkpd) model was developed to describe prolactin responses to risperidone (ris) and its active metabolite paliperidone (pal). |
2018-02-14 |
2023-08-13 |
rat |
| Hiroshi Kimura, Nobuhisa Kanahara, Tsuyoshi Sasaki, Naoya Komatsu, Minoru Ishige, Katsumasa Muneoka, Hidetoshi Ino, Kazuyuki Yoshimura, Hiroshi Yamanaka, Tomotaka Suzuki, Hideki Komatsu, Hiroyuki Watanabe, Eiji Shimizu, Masaomi Iy. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up. Journal of psychopharmacology (Oxford, England). vol 30. issue 8. 2018-01-04. PMID:27371496. |
risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: results of a 2-year prospective study, including an additional 1-year follow-up. |
2018-01-04 |
2023-08-13 |
Not clear |
| Hiroshi Kimura, Nobuhisa Kanahara, Tsuyoshi Sasaki, Naoya Komatsu, Minoru Ishige, Katsumasa Muneoka, Hidetoshi Ino, Kazuyuki Yoshimura, Hiroshi Yamanaka, Tomotaka Suzuki, Hideki Komatsu, Hiroyuki Watanabe, Eiji Shimizu, Masaomi Iy. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up. Journal of psychopharmacology (Oxford, England). vol 30. issue 8. 2018-01-04. PMID:27371496. |
maintaining thoroughly stable occupancy of the dopamine d2 receptor by risperidone long-acting injectable (rlai) is one strategy for treatment. |
2018-01-04 |
2023-08-13 |
Not clear |
| Geancarlo Zanatta, Gustavo Della Flora Nunes, Eveline M Bezerra, Roner F da Costa, Alice Martins, Ewerton W S Caetano, Valder N Freire, Carmem Gottfrie. Two Binding Geometries for Risperidone in Dopamine D3 Receptors: Insights on the Fast-Off Mechanism through Docking, Quantum Biochemistry, and Molecular Dynamics Simulations. ACS chemical neuroscience. vol 7. issue 10. 2017-06-21. PMID:27434874. |
two binding geometries for risperidone in dopamine d3 receptors: insights on the fast-off mechanism through docking, quantum biochemistry, and molecular dynamics simulations. |
2017-06-21 |
2023-08-13 |
Not clear |
| Michael De Santis, Jiamei Lian, Xu-Feng Huang, Chao Den. Early Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System. International journal of molecular sciences. vol 17. issue 11. 2017-04-04. PMID:27879654. |
the current study investigated potential long-term changes to the adult dopamine (da) system following aripiprazole, olanzapine and risperidone treatment in female and male juvenile rats. |
2017-04-04 |
2023-08-13 |
rat |
| Amit Taneja, An Vermeulen, Dymphy R H Huntjens, Meindert Danhof, Elizabeth C M De Lange, Johannes H Proos. A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats. European journal of pharmacology. vol 789. 2017-03-21. PMID:27395799. |
we compared the model performance of two semi-mechanistic pharmacokinetic-pharmacodynamic models, the precursor pool model and the agonist-antagonist interaction model, to describe prolactin response following the administration of the dopamine d2 receptor antagonists risperidone, paliperidone or remoxipride in rats. |
2017-03-21 |
2023-08-13 |
rat |